Page 73 - Read Online

Jayachandran et al. Hepatoma Res 2020;6:8 I http://dx.doi.org/10.20517/2394-5079.2019.35 Page 11 of 14

variability. Clin Liver Dis 2015;19:223-38.
9. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; Diseases AAftSoL. Diagnosis and management of hemochromatosis:
2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:328-43.
10. Liver EAFTSOT. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.
11. Crawford DHG. Hereditary hemochromatosis types 1, 2, and 3. Clin Liver Dis (Hoboken) 2014;3:96-7.
12. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet
Test 2000;4:183-98.
13. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, et al. A population-based study of the clinical expression of the
hemochromatosis gene. N Engl J Med 1999;341:718-24.
14. Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008;149:270-2.
15. Beutler E. Iron storage disease: facts, fiction and progress. Blood Cells Mol Dis 2007;39:140-7.
16. Gan EK, Powell LW, Olynyk JK. Natural history and management of HFE-hemochromatosis. Semin Liver Dis 2011;31:293-301.
17. Golfeyz S, Lewis S, Weisberg IS. Hemochromatosis: pathophysiology, evaluation, and management of hepatic iron overload with a
focus on MRI. Expert Rev Gastroenterol Hepatol 2018;12:767-78.
18. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, et al. Survival and causes of death in cirrhotic and in noncirrhotic
patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62.
19. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, et al. A novel MHC class I-like gene is mutated in patients with hereditary
haemochromatosis. Nat Genet 1996;13:399-408.
20. de Campos WN, Massaro JD, Cançado ELR, Wiezel CEV, Simões AL, et al. Comprehensive analysis of. World J Hepatol
2019;11:186-98.
21. Barton JC, Acton RT. HLA-A and -B alleles and haplotypes in hemochromatosis probands with HFE C282Y homozygosity in central
Alabama. BMC Med Genet 2002;3:9.
22. Adams PC, Barton JC. Haemochromatosis. Lancet 2007;370:1855-60.
23. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, et al. Iron-overload-related disease in HFE hereditary
hemochromatosis. N Engl J Med 2008;358:221-30.
24. Trifa AP, Popp RA, Militaru MS, Farcaş MF, Crişan TO, et al. HFE gene C282Y, H63D and S65C mutations frequency in the
Transylvania region, Romania. J Gastrointestin Liver Dis 2012;21:177-80.
25. Feder JN, Penny DM, Irrinki A, Lee VK, Lebrón JA, et al. The hemochromatosis gene product complexes with the transferrin receptor
and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998;95:1472-7.
26. Giannetti AM, Björkman PJ. HFE and transferrin directly compete for transferrin receptor in solution and at the cell surface. J Biol
Chem 2004;279:25866-75.
27. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The transferrin receptor modulates Hfe-dependent regulation of
hepcidin expression. Cell Metab 2008;7:205-14.
28. Vujić Spasić M, Kiss J, Herrmann T, Galy B, Martinache S, et al. Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab
2008;7:173-8.
29. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest 2013;123:2337-43.
30. Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program 2009;207-14.
31. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012;1823:1434-43.
32. Deugnier Y. Iron and liver cancer. Alcohol 2003;30:145-50.
33. Beutler E, Gelbart T, West C, Lee P, Adams M, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis
1996;22:187-94.
34. Mura C, Raguenes O, Férec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild
form of hemochromatosis. Blood 1999;93:2502-5.
35. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases.
Ann Intern Med 1999;130:953-62.
36. Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, et al. HFE C282Y/H63D compound heterozygotes are at low risk
of hemochromatosis-related morbidity. Hepatology 2009;50:94-101.
37. Walsh A, Dixon JL, Ramm GA, Hewett DG, Lincoln DJ, et al. The clinical relevance of compound heterozygosity for the C282Y and
H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006;4:1403-10.
38. Cardoso CS, de Sousa M. HFE, the MHC and hemochromatosis: paradigm for an extended function for MHC class I. Tissue Antigens
2003;61:263-75.
39. Torres FR, Souza-Neiras WC, D’Almeida Couto AA, D’Almeida Couto VS, Cavasini CE, et al. Frequency of the HFE C282Y and
H63D polymorphisms in Brazilian malaria patients and blood donors from the Amazon region. Genet Mol Res 2008;7:60-4.
40. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, et al. Survival and prognostic factors in 212 Italian patients with genetic
hemochromatosis. Hepatology 1992;15:655-9.
41. Kew MD. Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis: occurrence in noncirrhotic patients. Hepatology
1990;11:1086-7.
42. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, et al. Cancer risk in patients with hereditary hemochromatosis and in their
first-degree relatives. Gastroenterology 2003;125:1733-41.
43. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary
hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001;33:647-51.
44. Haddow JE, Palomaki GE, McClain M, Craig W. Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for
estimating the potential for primary prevention. J Med Screen 2003;10:11-3.